Drug Interaction Between Paracetamol and Warfarin
Launched by HOPITAL LARIBOISIÈRE · Apr 13, 2010
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Paracetamol is recommended as a first-line analgesic and antipyretic therapy in patients receiving short- and long-term oral anticoagulation, especially elderly patient.However,Increased INR was previously observed in patients treated with warfarin and paracetamol given at the maximum recommended dose (4g/day).
To date, the mechanism of this interaction has not been determined.A recent in vitro study suggested that the toxic metabolite N-acetyl-para-benzoquinoneimine (NAPQI) appeared to interfere with vitamin K-dependent γ-carboxylase (VKD-carb) and vitamin K epoxide reductase (VKOR) activ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients treated with warfarin (target INR 2 to 3) stable anticoagulation at 2 to 9 mg for more than 30 days
- • Aged 18 years or older
- • Laboratory values (hemoglobin, blood cell counts, albumin, blood ionogram, complementary hemostasis parameters and aspartate, alanine transaminases (AST and ALT))remained within normal limits
- Exclusion Criteria:
- • Any treatment change within 7 days before enrollment
- • Any paracetamol intake within the last 14 days
- • Drug allergy Concomitant drug ( 5-fluorouracile, acetylsalicylic acid, non steroidal anti-inflammatory drugs, chloramphenicol, diflunisal, miconazole)
- • St John's wort treatment
- • Pregnancy
About Hopital Lariboisière
Hôpital Lariboisière, a key institution within the Assistance Publique - Hôpitaux de Paris (AP-HP), is a renowned medical facility dedicated to providing high-quality patient care and advancing medical research. With a focus on innovative clinical trials, Hôpital Lariboisière aims to enhance treatment methodologies and improve patient outcomes across various medical specialties. The hospital's multidisciplinary approach fosters collaboration among healthcare professionals, ensuring rigorous adherence to ethical standards and regulatory requirements in clinical research. By prioritizing patient safety and scientific integrity, Hôpital Lariboisière is committed to contributing to the advancement of medical knowledge and the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Stephane Mouly, MD, PhD
Principal Investigator
Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboisière, Paris, France
Guy Simoneau, MD
Principal Investigator
Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboisière, Paris, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials